Literature DB >> 21398052

Changes in pulmonary function up to 10 years after locoregional breast irradiation.

Katrien Erven1, Caroline Weltens, Kristiaan Nackaerts, Steffen Fieuws, Marc Decramer, Yolande Lievens.   

Abstract

PURPOSE: To evaluate the long-term impact of locoregional breast radiotherapy (RT) on pulmonary function tests (PFTs). METHODS AND MATERIALS: This study included 75 women who underwent postoperative locoregional breast RT. PFTs were performed before RT and 3, 6, and 12 months and 8 to 10 years after RT. By use of univariate and multivariate analyses, the impact of treatment- and patient-related factors on late changes in PFTs was evaluated.
RESULTS: During the first year after RT, all PFTs significantly worsened at 3 to 6 months after RT (p < 0.05). At 12 months, forced vital capacity (FVC), vital capacity (VC), and forced expiratory volume in 1 second (FEV(1)) recovered almost to baseline values, whereas total lung capacity (TLC) and diffusion capacity of carbon monoxide (DL(CO)) recovered only slightly and were still found to be decreased compared with baseline (p < 0.05). At 8 to 10 years after RT, mean reductions in FEV(1) of 4% (p = 0.03) and in VC, DL(CO), and TLC of 5%, 9%, and 11% (all p < 0.0001), respectively, were observed compared with pre-RT values. On multivariate analysis, tamoxifen use negatively affected TLC at 8 to 10 years after RT (p = 0.033), whereas right-sided irradiation was associated with a late reduction in FEV(1) (p = 0.027). For FEV(1) and DL(CO), an early decrease was predictive for a late decrease (p = 0.003 and p = 0.0009, respectively).
CONCLUSIONS: The time course of PFT changes after locoregional RT for breast cancer follows a biphasic pattern. An early reduction in PFTs at 3 to 6 months with a partial recovery at 12 months after RT is followed by a late, more important PFT reduction up to 8 to 10 years after RT. Tamoxifen use may have an impact on this late decline in PFTs.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21398052     DOI: 10.1016/j.ijrobp.2010.12.058

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  16 in total

1.  Investigation of the evolution of radiation-induced lung damage using serial CT imaging and pulmonary function tests.

Authors:  Catarina Veiga; Edward Chandy; Joseph Jacob; Natalie Yip; Adam Szmul; David Landau; Jamie R McClelland
Journal:  Radiother Oncol       Date:  2020-03-30       Impact factor: 6.280

2.  Changes in pulmonary function and influencing factors after high-dose intrathoracic radio(chemo)therapy.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  Strahlenther Onkol       Date:  2016-10-25       Impact factor: 3.621

3.  A lot to a little or a little to a lot-which dose-volume relationship ensures the best clinical outcome in the high dose radiation therapy of thoracic tumors? A prospective approach.

Authors:  Christina Schröder; Rita Engenhart-Cabillic; Hilke Vorwerk; Michael Schmidt; Winfried Huhnt; Eyck Blank; Dietrich Sidow; André Buchali
Journal:  J Thorac Dis       Date:  2016-08       Impact factor: 2.895

4.  Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.

Authors:  Kathy Pan; Rowan T Chlebowski; Michael S Simon; Roberta M Ray; Jennifer Livaudais-Toman; Shannon D Sullivan; Marcia L Stefanick; Robert B Wallace; Meryl LeBoff; Elizabeth Carhart Bluhm; Electra D Paskett
Journal:  Breast Cancer Res Treat       Date:  2016-04-13       Impact factor: 4.872

5.  Concurrent or sequential letrozole with adjuvant breast radiotherapy: final results of the CO-HO-RT phase II randomized trial.

Authors:  C Bourgier; S Kerns; S Gourgou; C Lemanski; M Gutowski; P Fenoglietto; G Romieu; N Crompton; J Lacombe; A Pèlegrin; M Ozsahin; B Rosenstein; D Azria
Journal:  Ann Oncol       Date:  2015-12-17       Impact factor: 32.976

6.  Clinical relevance of radiation pneumonitis in breast cancers.

Authors:  Sushma Agrawal
Journal:  South Asian J Cancer       Date:  2013-01

Review 7.  Treatment techniques to reduce cardiac irradiation for breast cancer patients treated with breast-conserving surgery and radiation therapy: a review.

Authors:  Robert E Beck; Leonard Kim; Ning J Yue; Bruce G Haffty; Atif J Khan; Sharad Goyal
Journal:  Front Oncol       Date:  2014-11-14       Impact factor: 6.244

8.  Early detection and prediction of cardiotoxicity after radiation therapy for breast cancer: the BACCARAT prospective cohort study.

Authors:  Sophie Jacob; Atul Pathak; Denis Franck; Igor Latorzeff; Gaelle Jimenez; Olivier Fondard; Matthieu Lapeyre; Daniel Colombier; Eric Bruguiere; Olivier Lairez; Benoit Fontenel; Fabien Milliat; Radia Tamarat; David Broggio; Sylvie Derreumaux; Marianne Ducassou; Jean Ferrières; Dominique Laurier; Marc Benderitter; Marie-Odile Bernier
Journal:  Radiat Oncol       Date:  2016-04-07       Impact factor: 3.481

9.  Radiation pneumonitis and pulmonary function with lung dose-volume constraints in breast cancer irradiation.

Authors:  U Blom Goldman; M Anderson; B Wennberg; P Lind
Journal:  J Radiother Pract       Date:  2013-06-07

10.  Early Detection of Cardiovascular Changes After Radiotherapy for Breast Cancer: Protocol for a European Multicenter Prospective Cohort Study (MEDIRAD EARLY HEART Study).

Authors:  Valentin Walker; Anne Crijns; Johannes Langendijk; Daan Spoor; Rozemarijn Vliegenthart; Stephanie E Combs; Michael Mayinger; Arantxa Eraso; Ferran Guedea; Manuela Fiuza; Susana Constantino; Radia Tamarat; Dominique Laurier; Jean Ferrières; Elie Mousseaux; Elisabeth Cardis; Sophie Jacob
Journal:  JMIR Res Protoc       Date:  2018-10-01
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.